Rio’s research and development of novel clinical PET imaging tracers is dedicated to fluorine-18 (18F) appended small molecule ligands that possess high target specificity and binding potency to CNS transporter proteins. These transporter targets are specifically selected to report on regional CNS changes to key neurotransmitter networks. The 18F-labeled PET tracers have high target affinity, superior target selectivity and possess suitable PET scan properties to quantify target concentrations in live primate CNS tissues. The 18F-labeled tracers are suitable for production at remote facilities and shipment to far-flung diagnostic PET scanning clinics.
Quantify Neurological Disease Pathology in Vivo
Rio’s pipeline includes the following CNS transporter PET imaging 18F-tracers: |
CNS PET Tracer RP115 Neurotransmitter: Glutamate Protein Imaging Target: Excitatory Amino Acid Transporter 2 (EAAT2) Ongoing Development: Diagnostic clinical PET scan trials for Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS; motor neuron disease, MND) patients. CNS PET Tracer RP105 Neurotransmitter: Serotonin (5HT) Protein Imaging target: Serotonin Transporter (SERT) Ongoing Development: Non-human primate evaluations are completed. Toxicology of RP105 is planned for, as are healthy control and diagnostic clinical PET scan trials in amyotrophic lateral sclerosis (ALS; motor neuron disease, MND) patients.
CNS PET Tracer RP110 Neurotransmitter: Norepinephrine (NE) Protein Imaging target: Norepinephrine Transporter (NET) Ongoing Development: Non-human primate evaluations are completed. |   |